Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics
SLGL Price/Volume Stats
| Current price | $0.86 | 52-week high | $4.05 |
| Prev. close | $0.92 | 52-week low | $0.79 |
| Day low | $0.86 | Volume | 92,901 |
| Day high | $0.94 | Avg. volume | 29,120 |
| 50-day MA | $1.01 | Dividend yield | N/A |
| 200-day MA | $1.68 | Market Cap | 23.99M |
SLGL Stock Price Chart Interactive Chart >
Sol-Gel Technologies Ltd. (SLGL) Company Bio
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel
Latest SLGL News From Around the Web
Below are the latest news stories about SOL-GEL TECHNOLOGIES LTD that investors may wish to consider to help them evaluate SLGL as an investment opportunity.
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 StudySGT-610 has “Orphan Drug” designation status in the U.S. and E.U. and “Breakthrough Therapy” designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in Gorlin syndromeSol-Gel to host a virtual Key Opinion Leader event to discuss the Gorlin syndrome patient experience and treatment needs, as well as the SGT-610 Phase 3 trial on Wednesday, December 6th at 12 pm ET NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq |
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO |
Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?Key Insights Using the 2 Stage Free Cash Flow to Equity, Sol-Gel Technologies fair value estimate is US$1.87 Sol-Gel... |
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateSol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains cash runway into the second half of 2025 NESS ZIONA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved |
Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel TechnologiesDr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article. |
SLGL Price Returns
| 1-mo | -12.91% |
| 3-mo | -28.33% |
| 6-mo | -35.34% |
| 1-year | -76.44% |
| 3-year | -93.74% |
| 5-year | -88.22% |
| YTD | -22.17% |
| 2023 | -75.77% |
| 2022 | -38.38% |
| 2021 | -24.41% |
| 2020 | -42.92% |
| 2019 | 184.88% |
Continue Researching SLGL
Want to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...